Show simple item record

dc.contributor.authorvan der Moeren, N
dc.contributor.authorZwart, V F
dc.contributor.authorGoderski, G
dc.contributor.authorRijkers, G T
dc.contributor.authorvan den Bijllaardt, W
dc.contributor.authorVeenemans, J
dc.contributor.authorKluytmans, J A J W
dc.contributor.authorPas, S D
dc.contributor.authorMeijer, A
dc.contributor.authorVerweij, J J
dc.contributor.authorMurk, J L A N
dc.contributor.authorStohr, J J J M
dc.date.accessioned2021-07-21T08:58:02Z
dc.date.available2021-07-21T08:58:02Z
dc.date.issued2021-07-08
dc.identifier.pmid34271540
dc.identifier.doi10.1016/j.jcv.2021.104909
dc.identifier.urihttp://hdl.handle.net/10029/625163
dc.description.abstractThe DAA had an overall specificity of 100% (95%CI 97.9%-100%) and sensitivity of 73% (95%CI 61.3%-82.7%) for the clinical samples. Sensitivity was 86% (CI95% 74.6%-93.3%) for samples with Ct-value below 30. Both the DAA and RRA detected SARS-CoV-2 up to a dilution containing 5.2 × 102 fifty-percent-tissue-culture-infective-dose (TCID50)/ml.en_US
dc.language.isoenen_US
dc.rightsCopyright © 2021. Published by Elsevier B.V.
dc.subjectAntigen detection assayen_US
dc.subjectEvaluationen_US
dc.subjectSARS-CoV-2en_US
dc.titlePerformance of the Diasorin SARS-CoV-2 antigen detection assay on the LIAISON XL.en_US
dc.typeArticleen_US
dc.identifier.eissn1873-5967
dc.identifier.journalJ Clin Virol 2021; 141:104909en_US
dc.source.journaltitleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
dc.source.volume141
dc.source.beginpage104909
dc.source.endpage
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record